EVOQ Therapeutics

EVOQ Therapeutics is a biopharmaceutical company focused on developing innovative immunotherapies to treat autoimmune diseases. They are pioneering a proprietary technology that harnesses the body's natural immune system to restore immune tolerance. Their approach centers on utilizing a synthetic HDL NanoDisc designed to deliver antigens directly to dendritic cells, the key orchestrators of immune responses, within lymph nodes. This targeted delivery system has shown significant preclinical efficacy in models for multiple sclerosis and Type 1 Diabetes, demonstrating its potential to treat a wide range of autoimmune conditions.

EVOQ's commitment to innovation is reflected in their collaborations with leading pharmaceutical companies and research organizations like Amgen, Gilead, and JDRF. These partnerships are accelerating the development of their NanoDisc platform technology for treating diseases like rheumatoid arthritis, lupus, and type 1 diabetes. With a robust pipeline of disease-specific immune modulators, EVOQ is dedicated to delivering desperately needed treatments to patients suffering from autoimmune disorders.

EVOQ Therapeutics is a biopharmaceutical company dedicated to developing immunotherapies that improve the lives of individuals battling autoimmune diseases. Their mission is to utilize their proprietary NanoDisc technology to restore immune tolerance and reduce the body's aberrant immune response, ultimately providing novel and highly effective treatments for a range of autoimmune conditions including Type 1 diabetes, Celiac disease, Multiple sclerosis, Rheumatoid arthritis, and Lupus.

EVOQ Therapeutics cultivates a collaborative and innovative culture driven by a shared passion for developing groundbreaking immunotherapies to improve the lives of those battling autoimmune diseases. They value scientific rigor, cutting-edge research, and a commitment to translating discoveries into effective treatments. This dynamic environment fosters a sense of purpose and urgency as the team works together to address the critical unmet needs of patients worldwide.